Hepatocellular Carcinoma Clinical Trials in Nanjing
7 recruitingNanjing, China
Showing 1–7 of 7 trials
Recruiting
A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
HCC - Hepatocellular CarcinomaCTTACE(Transcatheter Arterial Chemoembolization)
Zhongda Hospital250 enrolled1 locationNCT07351669
Recruiting
Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech246 enrolled51 locationsNCT07176650
Recruiting
Early Phase 1
Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer
NSCLC (Advanced Non-small Cell Lung Cancer)HCC - Hepatocellular Carcinoma
Wondercel Biotech (ShenZhen)60 enrolled2 locationsNCT06653023
Recruiting
Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca1,220 enrolled204 locationsNCT06921785
Recruiting
Phase 2
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca114 enrolled24 locationsNCT07081633
Recruiting
Phase 3
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Hepatocellular Carcinoma
AstraZeneca210 enrolled32 locationsNCT05557838
Recruiting
Not Applicable
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
Unresectable Hepatocellular Carcinoma
Zhongda Hospital188 enrolled1 locationNCT06593964